Dataset for "Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)"
Supplementary file 1 contains the medical and product codes using from the Clinical Practice Research Datalink in defining the population to be included in this study.
Supplementary file 2 contains some further results and information about the cohort that were not included in the main publication but may be useful to aid understanding of the results found.
Cite this dataset as:
Ellis, J.,
McHugh, N.,
Pauling, J.,
Bruce, I.,
Charlton, R.,
McGrogan, A.,
Skeoch, S.,
2024.
Dataset for "Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)".
Bath: University of Bath Research Data Archive.
Available from: https://doi.org/10.15125/BATH-01404.
Export
Data
Supplementary evidence file2.pdf
application/pdf (639kB)
Creative Commons: Attribution 4.0
Further results for the study: Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD).
Code
Supplementary … 1_Skeoch (1).xlsx
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet (422kB)
Creative Commons: Attribution 4.0
Medical and product codes used in CPRD GOLD within the work described in Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD).
Creators
Jessica Ellis
University of Bath
Neil McHugh
University of Bath
John Pauling
University of Bath
Ian N Bruce
University of Manchester
Rachel Charlton
University of Bath
Anita McGrogan
University of Bath
Sarah Skeoch
University of Bath
Contributors
University of Bath
Rights Holder
Clinical Practice Research Datalink
Rights Holder
Documentation
Data collection method:
Methods are described in full in the paper. Briefly: * SLE Read codes, were identified from the CPRD dictionary and from review of code lists reported in previous CPRD studies. * Code lists were reviewed independently by two rheumatologists and those with agreement retained. * Clinical and immunological features suggestive of SLE based on the 2019 EULAR-ACR classification criteria were found. * Immunosuppressants were amended to include SLE related medications which are now more widely used (addition of Leflunomide, Mycophenolate Mofetil, Rituximab and Tacrolimus and Belimumab). * Test data (e.g. white cell count) had inclusion thresholds set based on unit types and expected normal values.
Data processing and preparation activities:
The cohort was selected as described in the case ascertainment section of the paper. Data was aggregated and described in the paper. No changes to the original data that we received (already deidentified) were made.
Technical details and requirements:
SQL Developer was used to process the raw data; analysis was carried out using R.
Additional information:
No coding included in these supplementary data files.
Funders
University of Bath
https://doi.org/10.13039/501100000835
Publication details
Publication date: 27 July 2024
by: University of Bath
Version: 1
DOI: https://doi.org/10.15125/BATH-01404
URL for this record: https://researchdata.bath.ac.uk/1404
Related papers and books
Ellis, J., McHugh, N., Pauling, J. D., Bruce, I. N., Charlton, R., McGrogan, A., and Skeoch, S., 2024. Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD). Lupus Science & Medicine, 11(2), e001213. Available from: https://doi.org/10.1136/lupus-2024-001213.
Related datasets and code
Clinical Practice Research Datalink, 2021. CPRD GOLD July 2021. Version 2021.07.001. Clinical Practice Research Datalink. Available from: https://doi.org/10.48329/YYCW-N139.
Contact information
Please contact the Research Data Service in the first instance for all matters concerning this item.
Contact person: Anita McGrogan
Life Sciences
Pharmacy & Pharmacology
